Company: GIFLF
Filing Date: 2025-04-11
Form Type: 20-F
Source: 0001104659-25-034245
Chunk: 76

Company: Grifols SA
Filing Date: 2025-04-11
Form: 20-F
Item: Item 4
Chunk 76
---
.

45

Certain sales regions, particularly in emerging markets, have experienced continuous growth, driven by enhanced socioeconomic conditions, including a general increase in the testing of patients for immunodeficiencies, autoimmune diseases and low levels of alpha 1 protein, all conditions treatable by our products, more informed patients who are demanding better quality medical care, as well as increasing government healthcare spending on plasma derivative products. These emerging markets are expected to experience significant growth. Our presence and experience in Latin America, in countries such as Mexico, Colombia, Argentina, Chile and Brazil, where we have been marketing and selling products for over 20 years, has positioned us to benefit from this additional growth in both our Biopharma and Diagnostic business units. In the Asia-Pacific region, we have established a presence through our subsidiaries and representative offices in Malaysia, China, Thailand, Singapore, Australia, Japan, India, Hong Kong, Taiwan and Indonesia. We have also opened a Middle Eastern representative office in Dubai and Saudi Arabia.
We maintain a continuing focus on international expansion and acquisitions and will continue to selectively consider acquisitions that would generate operation synergies. For specific examples of acquisitions we have made to further enhance our operations, see “—A. History and Development of the Company—Important Milestones” above.
The following chart reflects a summary of net revenue by each of our geographic regions for the past three years:

               ​                   ​        ​          ​          ​         ​          ​          ​          ​         ​          ​          ​          ​        ​
------------------------------------------------------------------------------------------------------------------------------------------------------------------
​                                        Year ended          ​                      Year ended          ​                      Year ended          ​              
​                                  ​   December 31,   ​      % of total    ​      December 31,   ​      % of total    ​      December 31,   ​      % of total     
Summary of Net Revenue by Region   ​           2024   ​      net revenue   ​              2023   ​      net revenue   ​              2022   ​      net revenue    
​                                  ​                                                                           (in thousands of euros, except for percentages)    
European Union(1)                         1,541,338   ​      21.4          %         1,255,927   ​      19.1          %         1,032,210   ​      17.0          %
United States and Canada                  4,087,030   ​      56.7          %         3,898,961   ​      59.1          %